Topical aminocaproic acid to prevent rebleeding in cases of traumatic hyphema.
OBJECTIVE
To determine the effect of topical aminocaproic acid on the incidence of rebleeding after traumatic hyphema.


METHODS
This randomized double blind clinical trial investigated 132 consecutive cases of traumatic hyphema referred to the emergency room of Farabi Eye Hospital in 1998-1999. The patients were randomly divided into three groups: Group 1 received cycloplegic drops only. Group 2 received cycloplegic drops and 2% carboxy polymethylene (CPM) gel as placebo. Group 3 was treated with cycloplegic drops and 25% aminocaproic acid (ACA) in CPM gel (supplied by Messrs. Sina Darou). All patients were treated for five days on an outpatient basis, with a two-week follow-up. The incidence of rebleeding, time needed for clot absorption, and complications of hyphema were recorded and analyzed using the chi-square and Student's t-tests and logistic regression modeling.


RESULTS
Rebleeding occurred in 8 eyes of 52 patients in group 1 (15.4%), 7 eyes of the 39 patients in group 2 (17.9%) and 5 eyes of the 41 patients in group 3 (12.2%). This difference was not significant. The time needed for clot absorption in groups 1, 2 and 3 was respectively 9.5 +/- 3.9, 9.3 +/- 4.2 and 11.15 +/- 4.7 days, the difference between group 3 and the other two groups being statistically significant (p<0.04).


CONCLUSIONS
Topical 25% ACA is not effective in reducing the incidence of rebleeding and lengthens the time needed for clot absorption.
Karkhaneh
R
R
Department of Ophthalmology, Tehran University of Medical Sciences, Farabi Eye Hospital, Tehran, Iran.
Naeeni
M
M
Chams
H
H
Abdollahi
M
M
Mansouri
M R
MR
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D015119:Aminocaproic Acid / Q000008:administration & dosage* / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004311:Double-Blind Method; D005131:Eye Injuries / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005782:Gels; D006801:Humans; D006988:Hyphema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D009883:Ophthalmic Solutions; D015990:Placebo Effect; D055502:Secondary Prevention; D016896:Treatment Outcome; D014792:Visual Acuity
D000933:Antifibrinolytic Agents; D005782:Gels; D009883:Ophthalmic Solutions; D015119:Aminocaproic Acid